Ranitidine OTC Private Labels Ready For January Launch
This article was originally published in The Tan Sheet
Executive Summary
At least three private label marketers will launch OTC 75 mg ranitidine immediately upon termination of Novopharm's 180-day marketing exclusivity Jan. 19. Perrigo, PL Developments and Zenith Goldline Pharmaceuticals showcased their versions of the H2 antagonist at the Private Label Manufacturers Association annual trade show in Chicago Nov. 14-16.